Quantbot Technologies LP Sells 44,148 Shares of Progyny, Inc. (NASDAQ:PGNY)

Quantbot Technologies LP reduced its stake in Progyny, Inc. (NASDAQ:PGNY) by 33.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 86,316 shares of the company’s stock after selling 44,148 shares during the period. Quantbot Technologies LP owned about 0.10% of Progyny worth $1,489,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Signaturefd LLC lifted its holdings in shares of Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after purchasing an additional 1,355 shares during the period. GAMMA Investing LLC boosted its position in shares of Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after purchasing an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after acquiring an additional 1,526 shares in the last quarter. Caitlin John LLC increased its stake in Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after purchasing an additional 3,183 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Progyny during the fourth quarter valued at about $74,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Stock Performance

NASDAQ PGNY opened at $22.05 on Tuesday. The company has a market capitalization of $1.88 billion, a P/E ratio of 38.02, a P/E/G ratio of 2.39 and a beta of 1.41. The company has a fifty day moving average of $21.96 and a 200-day moving average of $18.54. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $38.98.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on PGNY shares. Canaccord Genuity Group upped their price target on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, February 28th. JPMorgan Chase & Co. upped their price objective on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Finally, Bank of America lifted their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $24.82.

Insider Buying and Selling

In other news, Chairman David J. Schlanger purchased 150,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 12.30% of the stock is currently owned by corporate insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.